Related Experiment Video
Updated: Jul 4, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases
Giuseppe Altavilla1, Carmela Arrigo, Maria Carmela Santarpia
1Department of Medical Oncology (Pad. H 5 degrees piano), University of Messina, Via Consolare Valeria, 98125 Messina, Italy. galtavilla@unime.it
Abstract:
Brain metastases are a common occurrence and a major cause of mortality in non-small-cell lung cancer, with few systemic treatment options. Although targeting epidermal growth factor receptor-associated tyrosine kinase with erlotinib and gefitinib results in durable responses in some patients, the activity of these drugs against brain metastases has been poorly documented. In particular, few reports have so far reported the activity of erlotinib in this setting. Here we report the case of a male Italian smoker with an adeno-carcinoma of the lung whose lung cancer and brain metastases have both responded to erlotinib.
Insights
Erlotinib shows promise in treating non-small cell lung cancer brain metastases. This case study highlights erlotinib
Area of Science:
- Oncology
- Neurology
Background:
- Brain metastases are a significant cause of mortality in non-small-cell lung cancer (NSCLC).
- Systemic treatment options for NSCLC with brain metastases are limited.
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors like erlotinib show efficacy in some NSCLC patients, but their activity in brain metastases is poorly documented.
Observation:
- A case of a male Italian smoker with NSCLC and brain metastases was observed.
- The patient had adenocarcinoma of the lung.
Findings:
- Both primary lung cancer and brain metastases responded to erlotinib treatment.
- This case provides evidence for erlotinib's activity in NSCLC brain metastases.
Implications:
- Erlotinib may be an effective treatment option for NSCLC patients with brain metastases.
- Further research is warranted to confirm the efficacy and safety of erlotinib in this patient population.
- This finding could lead to improved therapeutic strategies for NSCLC with secondary brain tumors.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018